Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies
CONCLUSIONS: Clinicians should be aware that the prevalence of serious infections during alemtuzumab can be higher than expected from RCTs. Peculiar opportunistic infections should be considered when evaluating a patient treated with alemtuzumab who develops signs of infection.PMID:34310251 | DOI:10.1080/14740338.2021.1942454
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Antonio Riccardo Buonomo Giulio Viceconte Emanuela Zappulo Alberto Enrico Maraolo Cinzia Valeria Russo Antonio Carotenuto Marcello Moccia Ivan Gentile Source Type: research
More News: Aspergillosis | Drugs & Pharmacology | Hepatitis | Multiple Sclerosis | Respiratory Medicine | Study